Enasidenib is specifically approved for patients with relapsed or refractory AML who have mutations in the IDH2 gene. This mutation can be identified through genetic testing of the cancer cells. The drug offers a treatment option for patients who have not responded to or have relapsed following standard chemotherapy.
